Silexion Therapeutics (SLXN): Operating Sales Margin

Public company logo of Silexion Therapeutics Corp (SLXN)

The development of Silexion Therapeutics Corp (SLXN) is based on combating KRAS mutations and the success of SIL-204. The average operating margin demonstrates steady dynamics, where 0.00 captures the current state of the parameter. Financial stability is ensured by the non-cyclical nature of biotech and the absence of seasonality. Long-term contracts with laboratories and diversified logistics for RNA components guarantee process continuity, minimizing the risks of capital drawdown.

SLXN - Silexion Therapeutics Corp. Operating Profit Ratio over the range 08/17/2024 - 11/20/2026

Metric breakdowns and analytics for Silexion (SLXN)

- money and cash flow information:
Fundamental company valuation:silexion.com, SLXN
Finished products of Silexion Therapeutics Corp.

For Silexion Therapeutics Corp (SLXN), whose revenues depend on the commercialization of siRNA cancer drugs, the operating margin reflects the efficiency of managing development costs relative to revenue. This metric is calculated as the ratio of operating profit before interest and taxes to total sales, demonstrating the business's ability to generate cash flow. By analyzing this operating profitability chart, an investor determines the sustainability of the model and default risks.